Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
A new report from the University of Pennsylvania School of Veterinary Medicine has expanded what we know about the connection between myeloid-derived immunosuppressor cells (MDSCs) and aggressive disease. Their research has found that blocking the deltaNp63 protein on tumour cells which directs MDSCs to tumour and metastatic sites, or blocking the MDSCs themselves, reduces tumour growth and metastasis in a mouse model of triple-negative breast cancer (TNBC).
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth.
The NIH has awarded inaugural funding to three institutions to establish a new genome centre for the All of Us Research Program.
Rady Children’s Hospital has launched a new, California State-funded initiative called Project Baby Bear to cover rWGS for critically ill newborns across the state.
The development of the first automated DNA sequencers completely revolutionized the field of DNA sequencing and, eventually, made it possible to publish the first draft sequences of the human genome. Since then, a whole host of companies have developed their own approaches to DNA sequencing, resulting in a market that is filled with different possibilities […]
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Precision medicine is showing significant signs of success across tumour types.
Scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?
With artificial intelligence, machines can now examine thousands of medical images for signs of disease. Will this technology replace doctors – or work side by side with them?